Introduction {#section1-2050313X17741014}
============

Intraductal papillary mucinous neoplasm (IPMN) is characterized by the production of mucinous fluid by the tumor cells and tends to extend into a pancreatic duct. Development of imaging techniques and clinical advancements have led to more frequent recognition of IPMNs. Recently, IPMN of the pancreas has been found to be highly prevalent in the general population, and these tumors account for 8%--20% of all resected pancreatic neoplasms.^[@bibr1-2050313X17741014][@bibr2-2050313X17741014]--[@bibr3-2050313X17741014]^ IPMNs may be left untreated, but some may progress to invasive cancer (i.e. transform from a benign to a malignant tumor).^[@bibr1-2050313X17741014][@bibr2-2050313X17741014]--[@bibr3-2050313X17741014]^

We present a case of life-threatening spontaneous rupture of an IPMN, causing massive bleeding that appeared during follow-up in a patient with a pancreatic IPMN. Although acute pancreatitis, perforation, and fistula formation of pancreatic IPMNs have been reported,^[@bibr4-2050313X17741014][@bibr5-2050313X17741014][@bibr6-2050313X17741014]--[@bibr7-2050313X17741014]^ to the best of our knowledge, there have been no previous reports of IPMN rupture, causing life-threatening bleeding.

Case presentation {#section2-2050313X17741014}
=================

A 74-year-old woman complained of acute upper right abdominal pain and became unconscious. She had been followed every 6 months for an IPMN in the pancreatic head ([Figure 1(a)](#fig1-2050313X17741014){ref-type="fig"}), with no mural nodules and no changes in the size of the tumor over the past 5 years on abdominal ultrasonography and computed tomography (CT). She had no history of acute pancreatitis, and was not on medication including anticoagulant drugs. Levels of serum tumor markers (carcinoembryonic antigen and carbohydrate antigen 19-9) were within normal limits.

![Patient with intraductal papillary mucinous neoplasm (IPMN) and intra-abdominal bleeding: (a) a 74-year-old woman was followed for IPMN in the pancreatic head (arrowheads). The size did not change for 5 years. (b) Contrast-enhanced computed tomography showed IPMN rupture and intra-abdominal bleeding (arrowheads).](10.1177_2050313X17741014-fig1){#fig1-2050313X17741014}

The abdomen was distended, and the shock index (defined as heart rate/systolic blood pressure) was 1.5 (blood pressure, 87/42 mm Hg; pulse 130 beats/min). The hemoglobin level was 6.1 g/dL. She became hemodynamically unstable with hypotension. Contrast-enhanced CT on admission revealed a massive hematoma spreading into the abdominal cavity, suggestive of an IPMN rupture. The main pancreatic duct was not dilated on CT ([Figure 1(b)](#fig1-2050313X17741014){ref-type="fig"}). Transfusion of packed red blood cells was followed by fluid overload. As her blood pressure was unstable, transarterial embolization (TAE) was initially selected. A 1.8-Fr coaxial microcatheter was advanced near the bleeding point of a branch of the gastroduodenal artery (GDA). TAE was performed using a gelatin sponge ([Figure 2](#fig2-2050313X17741014){ref-type="fig"}). After TAE, the patient became hemodynamically stable. Pylorus-preserving pancreaticoduodenectomy was performed 7 days later. During the operation, a ruptured cystic mass with hematoma was seen in the pancreatic head, and the tumor was completely removed with tumor-free margins ([Figure 3(a)](#fig3-2050313X17741014){ref-type="fig"}).

![Digital subtraction angiography images: (a) arteriography of a gastroduodenal artery (GDA) branch (superior pancreaticoduodenal artery) demonstrated tumor bleeding (arrowhead) and (b) a microcatheter was advanced near the bleeding point of the posterior superior pancreaticoduodenal artery (arrowhead). Embolization was performed using a gelatin sponge.](10.1177_2050313X17741014-fig2){#fig2-2050313X17741014}

![Macroscopic and pathological findings: (a) macroscopic observations revealed that the resected cystic mass comprised a dark red, partially organized hematoma; (b) pathological examination revealed a growing papillary tumor characterized by low-grade dysplasia in the intrapancreatic duct; and (c) focal infiltration of hemosiderin-laden macrophages was observed in the pancreatic parenchyma.](10.1177_2050313X17741014-fig3){#fig3-2050313X17741014}

Upon microscopic examination, the resected specimen showed a growing papillary tumor characterized by low-grade dysplastic cells in the intrapancreatic duct ([Figure 3(b)](#fig3-2050313X17741014){ref-type="fig"}), with a hematoma due to fresh and old bleeding. Focal infiltration of hemosiderin-laden macrophages was observed in the pancreatic parenchyma ([Figure 3(c)](#fig3-2050313X17741014){ref-type="fig"}). The final diagnosis was gastric-type IPMN with low-grade dysplasia, with intravascular emboli of the carcinoma type. The patient had an uneventful postoperative recovery without complications. In the approximately 2 years since the operation, there has been no sign of recurrence.

Discussion {#section3-2050313X17741014}
==========

IPMN of the pancreas is a distinct entity and is characterized by the proliferation of mucin-producing papillary epithelial cells, resulting in excessive mucus production and cystic dilatation of the pancreatic ducts. Various complications associated with IPMNs have been reported, including acute pancreatitis, intraductal bleeding, duct perforation, and fistula formation into the duodenum, common bile duct, and stomach.^[@bibr4-2050313X17741014][@bibr5-2050313X17741014][@bibr6-2050313X17741014][@bibr7-2050313X17741014][@bibr8-2050313X17741014]--[@bibr9-2050313X17741014]^ Even a non-malignant tumor may carry the risk of spontaneous rupture or bleeding.

The MEDLINE database was used to search for all English-language articles describing IPMNs in the pancreas complicated by bleeding or pancreatic duct rupture, and all relevant references cited in the identified articles were reviewed ([Table 1](#table1-2050313X17741014){ref-type="table"}).^[@bibr1-2050313X17741014],[@bibr6-2050313X17741014],[@bibr10-2050313X17741014][@bibr11-2050313X17741014][@bibr12-2050313X17741014][@bibr13-2050313X17741014][@bibr14-2050313X17741014]--[@bibr15-2050313X17741014]^ In all cases, the size of the tumor was greater than 20 mm, or the duct dilation was greater than 10 mm. There was no case with both intraductal bleeding and rupture of the pancreatic duct.

###### 

Case reports of intraductal papillary mucinous neoplasms (IPMNs) in the pancreas complicated with intraductal bleeding pancreatic duct rupture.

![](10.1177_2050313X17741014-table1)

                                                   Age/sex     Site of tumor   Size (cm)   Duct dilation   Symptom   Operation          Histological diagnosis          Rupture                       Bleeding
  ------------------------------------------------ ----------- --------------- ----------- --------------- --------- ------------------ ------------------------------- ----------------------------- ------------------------------
  Zanelli et al.^[@bibr10-2050313X17741014]^       49/M        Diffuse & RP    6           NS              AP        PPPD               NS                              (+) Pseudomyxoma peritonei    (−)
  Mizuta et al.^[@bibr11-2050313X17741014]^        53/M        Tail            2           Mild            AF, LOA   Omental excision   NS                              (+) Pseudomyxoma peritonei    (−)
  Imaoka et al.^[@bibr12-2050313X17741014]^        64/M        Tail            NS          Severe          AP        DP                 IV                              (+) Pseudomyxoma peritonei    (−)
  Lee et al.^[@bibr6-2050313X17741014]^            55/M        Body/tail       8.5         NS              None      DP                 IV                              (+) Pseudomyxoma peritonei    (−)
  Nepka et al.^[@bibr13-2050313X17741014]^         82/M        NS              NS          20 mm           Ascites   None               NS                              (+) Pseudomyxoma peritonei    (−)
  Rosenberger et al.^[@bibr14-2050313X17741014]^   75/M        Tail            20          14.1 mm         None      DP                 Moderate dysplasia              (+) Focally                   (−)
  75/M                                             Head        3.5             10 mm       None            PPPD      IV                 (+) Focally                     (−)                           
  Nagano et al.^[@bibr15-2050313X17741014]^        71/M        Head            3.5         NS              LOA       PPPD               IV                              (+) Biliopancreatic fistula   (−)
  Yamada et al.^[@bibr1-2050313X17741014]^         65/M        Head            NS          38 mm           AP        PPPD               IPMA                            (−)                           (+) Intraductal
  60/M                                             Tail        NS              28 mm       AP              DP        IPMA               (−)                             (+) Intraductal               
  73/M                                             Head        NS              30 mm       None            PPPD      IPMC               (−)                             (+) Intraductal               
  77/F                                             Body/tail   NS              25 mm       None            DP        IPMA               (+) Focally                     (+) Intraductal               
  71/M                                             Head/tail   NS              40 mm       None            TP        IV                 (+) Into duodenal and jejunal   (+) Intraductal               
  Present case                                     74/F        Head            5.5         None            AP        PPPD               Low-grade dysplasia             (+)                           (+) Intra-abdominal bleeding

RP: retroperitoneal; NS: not stated; AP: abdominal pain; PPPD: pylorus-preserving pancreaticoduodenectomy; AF: abdominal fullness; LOA: loss of appetite; DP: distal pancreatectomy; IV: invasive carcinoma; IPMA: intraductal papillary mucinous adenoma; IPMC: intraductal papillary mucinous carcinoma; TP: total pancreatectomy.

In many cases in the literature review, the tumors were malignant, and pancreatic duct dilation was seen. This may be accounted for by the fact that the tumor characteristics may change over time.

Some of the causative factors for intraductal bleeding in IPMN have been considered. Stasis of pancreatic flow of mucinous materials in the dilated pancreatic ducts might place high-pressure stress on the tumor, and this may play an important role in denuding the epithelium.^[@bibr1-2050313X17741014]^ Kurihara et al.^[@bibr5-2050313X17741014]^ described several processes, including potential fistula formation due solely to mechanical pressure from expansion by the tumor and/or thick mucus, accompanied by stromal invasion of the cancer and rupture through mucinous lakes within the stroma. In our patient, the cause of IPMN rupture and massive bleeding was not clear. Pancreatic pseudocysts sometimes develop intracystic bleeding, and there is a possibility that bleeding occurred into the IPMN cavity and formed a hematoma in our case. However, the histopathology of the surgical specimen showed epithelial lining within the cyst, and our patient had no history of acute pancreatitis or external injuries. For this reason, we believe that our case represented IPMN-associated hemorrhage.

The possible mechanism underlying IPMN rupture with intra-abdominal hemorrhage was as follows. The pancreatic cyst wall was lined by neoplastic cells. Bleeding of the neoplastic cell lining might have repeatedly occurred in the cyst, leading to breakdown and neovascularization. Mucinous materials and hematomas in the pancreatic cyst might have placed high-pressure stress upon the tumor epithelium. As a result, spontaneous rupture might have occurred.

Spontaneous IPMN rupture and bleeding are infrequent, but may be life-threatening. Even in patients with non-malignant IPMNs, follow-up examination may be needed if the size of the tumor was greater than 20 mm, or duct dilation was greater than 10 mm. We surmised that early preoperative diagnosis was important for effective management.

Conclusion {#section4-2050313X17741014}
==========

We reported a patient with pancreatic IPMN, resulting in massive and life-threatening bleeding. The findings from our case and a literature review indicated that pancreatic IPMN may carry a risk of spontaneous rupture with bleeding. Follow-up examinations are recommended even for IPMN patients without malignant findings because of the potential risk of rupture and bleeding with intra-abdominal hemorrhage. Clinicians should be aware of this possibility to ensure that patients are appropriately treated.
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